Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORS-PCOS: Resistant Starch in Polycystic Ovary Syndrome
NCT06852365Phase 2Recruiting
- Sponsor
- University of Pennsylvania
- Start
- Jun 2025
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 2, randomised trial in polycystic ovary syndrome (PCOS) and metabolic syndrome (2 arms), sponsored by University of Pennsylvania. Primary endpoints: Low-Density Lipoprotein Cholesterol at 12 weeks, Fasting Glucose at 12 weeks and 5 more. Started Jun 2025; status: recruiting.
02
Conditions
polycystic ovary syndrome (PCOS)metabolic syndrome
Beyond the preview
Go deeper on NCT06852365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06852365.